Numinus just pulled off its first legal harvest of psilocybe

Published Oct 27, 2020 09:00 a.m. ET
iStock / IgorChus

Numinus, a company known for creating an ecosystem of health solutions centred around supporting evidence-based safe, accessible use of psychedelic-assisted psychotherapies, has now harvested their very first legal flush of Psilocybe mushrooms in Canada, under a Health Canada-issued Controlled Drugs and Substances Dealer’s License issued to a public company.

Other recent developments by this company include a 7,000 square foot analytics and research lab. The lab is focused on various psychedelic substances. The development of analytical methods and formulations for the evolving psychedelic space is also in the company's eyesight.

Michael Tan, Chief Operating Officer at the company, is confident that the whole industry can now move forward and progress with research and development of standard cultivation by exploring product formulations and testing methods and supporting evidence-based accessible psychedelic-assisted psychotherapy. They will also offer assistance in the development of a spore library.

Dennis McKenna, Co-founder of Heffter Research Institution and member of Numinus General Advisory Council, adds that there is possibly a place for synthetic psilocybin in clinical practice. However, standardized extracts of the natural forms of psilocybin or magic mushrooms, which are cultivated under very stringent quality control protocols, are the way of the future. This is as therapeutic psilocybin begins to gain acceptance.

Numinus Research and Development is beginning to implement science while leveraging relationships to develop medical and therapeutic protocols for influencing regulatory approvals. While establishing itself as a forefront runner of analytical testing for psychedelic substances, Numinus continues to be a center of excellence for psychedelic product research. The company has included an amendment application to its Health Canada-issued Controlled Drugs and Substances License.

The current license permits:

  • Importing

  • Exporting

  • Undertaking novel mycological research initiatives

  • Export distribution and storage of Psilocybin, Psilocin, Mescaline, and DMT

With the amendment, the application will include the sale of Psilocybin mushroom fruiting bodies and extracts to facilitate clinical research protocol and standard testing for additional psychedelic substances.

Benefits of the magic mushroom

The magic mushroom, also known as Psilocybin, contains hallucinogens that can result in people hearing, seeing, or feeling things that are not there. Anxiety and fear may also be part of the magic mushroom experience. Today Psilocybin is being studied for its potential to help and treat various health conditions, including:

  • Depression

  • Anxiety

  • Obsessive-compulsive disorder

  • Problematic drug use

For these studies, the participant is administered the magic mushroom in clinically supervised situations. Researchers have tested the effects on patients when they are given a single-dose one time use of psilocybin with the combination of psychotherapy for individuals living with depression, anxiety, and cancer patients.

The results of the study indicated the use of magic mushrooms in the proper setting benefited patients immediately. It continued until six months later, for 70 percent of those that participated in the study.A smaller group of the original study members indicated that four years later, the subjects continued to sustain their reduction in depression, hopelessness, demoralization, and anxiety.

Final words

Magic mushrooms have been used in traditional medicine for thousands of years. Natural mushroom extracts are more likely to be affordable when compared to synthetic psilocybin. Money should not be a barrier for people who want to access these valuable medicines. Using mushroom extracts is going to be a beneficial help to those that need psilocybin therapies.

Studies conducted on magic mushroom use for specific conditions have indicated a positive benefit for those living and suffering from treatment-resistant anxiety and depression. The results are significant for cancer patients who are having difficulty treating their conditions with traditional methods. Gabby Agin-Liebe's lead author of a recent study indicates that the drug can facilitate profound, meaningful experiences that stay with a person and that it can fundamentally change one's mindset and outlook.

New campaign asks voters in Oregon to say yes to psilocybin therapy

Author

Related posts